High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy

PURPOSE: Tumor mutational burden (TMB) is a surrogate biomarker of neo-antigens and high TMB status is associated with favorable response to immune-checkpoint inhibitors (ICIs). This study aimed to elucidate the association between TMB and the outcome of definitive radiotherapy in patients with cerv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Norichika, Yoshimoto, Yuya, Darwis, Narisa Dewi Maulany, Sato, Hiro, Ando, Ken, Oike, Takahiro, Ohno, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068645/
https://www.ncbi.nlm.nih.gov/pubmed/34860358
http://dx.doi.org/10.1007/s11604-021-01230-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068645/
https://www.ncbi.nlm.nih.gov/pubmed/34860358
http://dx.doi.org/10.1007/s11604-021-01230-5

Ejemplares similares